Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMRION's FIRST PRODUCT UNDER IdB JOINT VENTURE WILL BE BILBERRY 20/20

This article was originally published in The Tan Sheet

Executive Summary

AMRION's FIRST PRODUCT UNDER IdB JOINT VENTURE WILL BE BILBERRY 20/20, an "optometric formula for the eyes containing bilberry and other antioxidants," the Boulder, Colo.-based vitamin and nutritional supplement company said in a May 18 press release. The joint venture agreement with Indena USA, the U.S. branch of Milan, Italy-based IdB Holding, gives Amrion access to one of the largest suppliers of botanical extracts in the world. A newly formed Amrion subsidiary, Natrix International, will be responsible for marketing the joint venture's products in the U.S.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel